LEXINGTON, Mass. & NEW YORK--(BUSINESS WIRE)--Concert Pharmaceuticals, Inc. and Fast Forward, LLC, the National Multiple Sclerosis Society’s subsidiary devoted to bridging the gap between research and drug development, today announced a new collaboration to fund the preclinical advancement of C-21191, a deuterium-modified subtype-selective GABAA modulator developed by Concert with the therapeutic potential of treating spasticity and pain in multiple sclerosis (MS). Fast Forward will commit funding to support the program for prospective clinical stage development.
